Addex Therapeutics (NASDAQ:ADXN) Rating Reiterated by HC Wainwright

HC Wainwright reiterated their buy rating on shares of Addex Therapeutics (NASDAQ:ADXN) in a report published on Wednesday morning, Benzinga reports. They currently have a $30.00 target price on the stock. HC Wainwright also issued estimates for Addex Therapeutics’ FY2024 earnings at $0.49 EPS, Q2 2025 earnings at $0.00 EPS, Q3 2025 earnings at $0.00 EPS, Q4 2025 earnings at $0.00 EPS and FY2025 earnings at ($0.28) EPS.

Addex Therapeutics Stock Performance

Shares of NASDAQ ADXN opened at $9.44 on Wednesday. Addex Therapeutics has a one year low of $5.00 and a one year high of $27.90. The firm has a market capitalization of $10.01 million, a P/E ratio of -0.55 and a beta of 1.79. The company’s fifty day moving average is $9.20 and its two-hundred day moving average is $10.56.

Addex Therapeutics (NASDAQ:ADXN) last announced its quarterly earnings data on Monday, September 30th. The company reported ($1.77) EPS for the quarter, missing the consensus estimate of ($0.07) by ($1.70). Addex Therapeutics had a negative net margin of 818.50% and a negative return on equity of 364.24%. The company had revenue of $0.13 million during the quarter, compared to analyst estimates of $0.26 million. On average, sell-side analysts forecast that Addex Therapeutics will post -0.36 earnings per share for the current fiscal year.

Addex Therapeutics Company Profile

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder.